Jia Yuan Tong
Direktor/Vorstandsmitglied bei Xynomic Pharmaceuticals, Inc.
Profil
Jia Yuan Tong currently works at Xynomic Pharmaceuticals, Inc., as Director.
Dr. Tong also formerly worked at Tianyin Pharmaceutical Co., Inc., as Chief Financial Officer & Director from 2011 to 2014, Bison Capital Acquisition Corp., as Chief Executive & Financial Officer, Director from 2016 to 2017, Xynomic Pharmaceuticals Holdings, Inc., as Executive Director, Chief Strategy Officer & EVP, ROTH Capital Partners LLC, as Research Analyst from 2008 to 2009, Rodman & Renshaw LLC (Old), as Research Associate, the University of California, Irvine, as Senior Research Fellow, and The Marine Biological Laboratory, as Principal Investigator.
Dr. Tong received his undergraduate degree and doctorate degree from Peking University and graduate degree from the University of California, Irvine.
Aktive Positionen von Jia Yuan Tong
Unternehmen | Position | Beginn |
---|---|---|
Xynomic Pharmaceuticals, Inc.
Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jia Yuan Tong
Unternehmen | Position | Ende |
---|---|---|
TIANYIN PHARMACEUTICAL INC CO | Finanzdirektor/CFO | 31.12.2014 |
ROTH Capital Partners LLC
ROTH Capital Partners LLC Investment Banks/BrokersFinance ROTH Capital Partners LLC is a broker/dealer headquartered in Newport Beach, California. The firm was founded in 2001 and is a subsidiary of CR Financial Holdings, Inc. They offer institutional sales and trading services. Their broad institutional coverage includes investors in North America, Canada, UK, Europe and other international territories. | Analyst-Equity | 30.06.2009 |
Rodman & Renshaw LLC (Old)
Rodman & Renshaw LLC (Old) Investment Banks/BrokersFinance Founded in 2003 by Cliff Rodman and Charles Renshaw, Rodman & Renshaw LLC is a full-service investment bank and broker/dealer located in New York City with an additional office in Boston. The firm is a subsidiary of Rodman & Renshaw Capital Group (NasdaqGM: RODM). The firm provides corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. They also provide research and sales and trading services to institutional investors. Rodman & Renshaw is a leader in the PIPE and RD (registered direct offering) transaction markets. The firm's research focuses on Asia, clean technology, community & regional banks, energy, industrial and commercial services, life science/healthcare and metals and mining. Rodman & Renshaw is a member of the NASD and the SIPC. | Analyst-Equity | 31.03.2008 |
XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Direktor/Vorstandsmitglied | - |
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Vorstandsvorsitzender | - |
Ausbildung von Jia Yuan Tong
Peking University | Doctorate Degree |
University of California, Irvine | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 7 |
---|---|
ROTH Capital Partners LLC
ROTH Capital Partners LLC Investment Banks/BrokersFinance ROTH Capital Partners LLC is a broker/dealer headquartered in Newport Beach, California. The firm was founded in 2001 and is a subsidiary of CR Financial Holdings, Inc. They offer institutional sales and trading services. Their broad institutional coverage includes investors in North America, Canada, UK, Europe and other international territories. | Finance |
Rodman & Renshaw LLC (Old)
Rodman & Renshaw LLC (Old) Investment Banks/BrokersFinance Founded in 2003 by Cliff Rodman and Charles Renshaw, Rodman & Renshaw LLC is a full-service investment bank and broker/dealer located in New York City with an additional office in Boston. The firm is a subsidiary of Rodman & Renshaw Capital Group (NasdaqGM: RODM). The firm provides corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. They also provide research and sales and trading services to institutional investors. Rodman & Renshaw is a leader in the PIPE and RD (registered direct offering) transaction markets. The firm's research focuses on Asia, clean technology, community & regional banks, energy, industrial and commercial services, life science/healthcare and metals and mining. Rodman & Renshaw is a member of the NASD and the SIPC. | Finance |
Tianyin Pharmaceutical Co., Inc.
Tianyin Pharmaceutical Co., Inc. Pharmaceuticals: OtherHealth Technology Tianyin Pharmaceutical Co., Inc. is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and other pharmaceuticals in China. Its products address significant medical needs in the therapeutic areas spanning internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, orthopedics, dermatology and pediatrics. The company was founded on March 31, 1994 and is headquartered in Chengdu, China. | Health Technology |
The Marine Biological Laboratory
The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services The Marine Biological Laboratory provides research and educational services. It offers a range of courses, workshops, conferences, and internships, discovery-based education programs and courses. The firm s a private marine laboratory, supporting scientists and staff working in such fields as cell and developmental biology, ecology, microbiology, molecular evolution, global infectious disease, neurobiology, and sensory physiology. The company was founded in 1888 and is headquartered in Woods Hole, MA. | Commercial Services |
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Finance |
Xynomic Pharmaceuticals, Inc.
Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Health Technology |
Xynomic Pharmaceuticals Holdings, Inc.
Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |